CXS | Suspension at close of trading 21/6/11 | PRICE SENSITIVE | 21/06/11 | | Share |
CXS | Notice of Compulsory Acquisition | PRICE SENSITIVE | 14/06/11 | | Share |
CXS | Notice of Variation of Offer: Extension of Offer Period | PRICE SENSITIVE | 14/06/11 | | Share |
CXS | Notice Under Sec 630(3) - Status of Defeating Conditions | PRICE SENSITIVE | 06/06/11 | | Share |
CXS | Notice under Sec 650F re Cephalon T/O | PRICE SENSITIVE | 01/06/11 | | Share |
CXS | Extension of Office Period | PRICE SENSITIVE | 27/05/11 | | Share |
CXS | Notice under Section 650F of Corps Act | PRICE SENSITIVE | 27/05/11 | | Share |
CXS | Cephalon CXS Holdings PL Notice of Acceptances | PRICE SENSITIVE | 27/05/11 | | Share |
CXS | Supplementary Bidder's Statement | PRICE SENSITIVE | 20/05/11 | | Share |
CXS | Variation of Takeover Bid | PRICE SENSITIVE | 13/05/11 | | Share |
CXS | Supplementary Bidder's Statement | PRICE SENSITIVE | 04/05/11 | | Share |
CXS | First Supplementary Bidder's Statement | PRICE SENSITIVE | 29/04/11 | | Share |
CXS | Off market takeover bid by Cephalon | PRICE SENSITIVE | 27/04/11 | | Share |
CXS | Bidder's Statement and Target's Statement | PRICE SENSITIVE | 13/04/11 | | Share |
CXS | Cephalon Launches Takeover Bid | PRICE SENSITIVE | 29/03/11 | | Share |
CXS | Half Yearly Report and Accounts | PRICE SENSITIVE | 18/02/11 | | Share |
CXS | ChemGenex to Align European and US Regulatory Strategies | PRICE SENSITIVE | 05/01/11 | | Share |
CXS | Awarded U.S. Therapeutic Discovery grant | PRICE SENSITIVE | 02/11/10 | | Share |
CXS | Convertible Note Issued to Cephalon, Inc | PRICE SENSITIVE | 22/10/10 | | Share |
CXS | Response to an ASX Price Query | PRICE SENSITIVE | 05/10/10 | | Share |
CXS | ChemGenex Completes pre-NDA Meeting with U.S. FDA | PRICE SENSITIVE | 05/10/10 | | Share |
CXS | FDA agrees on potential regulatory pathway for OMAPRO | PRICE SENSITIVE | 14/07/10 | | Share |
CXS | Complete Response Letter from FDA Received | PRICE SENSITIVE | 12/04/10 | | Share |
CXS | ODAC seeks validated diganostic before approval of OMAPRO | PRICE SENSITIVE | 23/03/10 | | Share |
CXS | Half Yearly Report and Accounts | PRICE SENSITIVE | 25/02/10 | | Share |
CXS | ODAC Postponed Due to Extreme Weather in Washington DC | PRICE SENSITIVE | 09/02/10 | | Share |
CXS | Omapro ODAC meeting confirmed for 10 February 2010 | PRICE SENSITIVE | 17/12/09 | | Share |
CXS | Omacetaxine European rights licensed to Hospira | PRICE SENSITIVE | 14/12/09 | | Share |
CXS | Updated omacetaxine data from multiTKI failure study | PRICE SENSITIVE | 09/12/09 | | Share |
CXS | Omapro Data Highlighted at ASH Press Conference | PRICE SENSITIVE | 07/12/09 | | Share |
CXS | EMEA validates ChemGenex's MAA for omacetaxine | PRICE SENSITIVE | 27/11/09 | | Share |
CXS | US FDA accepts Omapro NDA - grants priority review | PRICE SENSITIVE | 10/11/09 | | Share |
CXS | Omacetaxine Kills Leukemic Stem Cells in Human CML Models | PRICE SENSITIVE | 09/06/09 | | Share |
CXS | Omacetaxine Shows Activity in Refractory CML | PRICE SENSITIVE | 09/06/09 | | Share |
CXS | Omacetaxine Clinical Data Presented at ASCO | PRICE SENSITIVE | 02/06/09 | | Share |
CXS | Rights Issue Fully Subscribed, Further $1 Million Placement | PRICE SENSITIVE | 27/05/09 | | Share |
CXS | Information Booklet for Shareholders | PRICE SENSITIVE | 21/04/09 | | Share |
CXS | Placement and Non-Renounceable Rights Issue | PRICE SENSITIVE | 09/04/09 | | Share |
CXS | Reinstatement to Official Quotation | PRICE SENSITIVE | 09/04/09 | | Share |
CXS | Suspension from Official Quotation | PRICE SENSITIVE | 08/04/09 | | Share |
CXS | New Data Suggests Omacetaxine Eradicates Leukemic Stem Cells | PRICE SENSITIVE | 27/03/09 | | Share |
CXS | Half Yearly Report and Accounts | PRICE SENSITIVE | 25/02/09 | | Share |
CXS | FDA Grants Orphan Drug Designation to Omacetaxine for MDS | PRICE SENSITIVE | 20/01/09 | | Share |
CXS | Interim Clinical Trial Results Presented at ASH Conference | PRICE SENSITIVE | 09/12/08 | | Share |